Oramed Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
Oramed Pharmaceuticals Inc., a Jerusalem-based clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, has enrolled over 50% of patients planned for its Phase 2 trial of…
Continue Reading
Oramed Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment